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Abstract
Peroxisome proliferator–activated receptor-; (PPAR-
;) is a ligand-activated transcription factor. In addition
to its canonical role in lipid and glucose metabolism,
PPAR-; controls cell proliferation, death, and differ-
entiation in several tissues. Here we have examined
the expression of PPAR-; in ovarian tumors and the
cellular andmolecular consequences of its activation in
ovarian cancer cells. PPAR-; was expressed in a large
number of epithelial ovarian tumors and cell lines. The
PPAR-; ligand ciglitazone inhibited the growth and
clonogenic survival of ovarian cancer cells, inducing
cell cycle arrest and cell death. Growth inhibition by
ciglitazone was reversed by the PPAR-; antagonist
GW9662, indicating the involvement of PPAR-;–
dependent mechanisms. Microarray-based gene pro-
filing revealed complex changes in the transcriptional
program of ovarian cancer cells on treatment with
ciglitazone and identified multiple pathways that may
contribute to PPAR-; ligands’ antitumor activity. Genes
upregulated by ciglitazone were predominantly as-
sociated with metabolic, differentiation, and tumor-
suppressor pathways, whereas downregulated genes
were involved in cell proliferation, cell cycle, cell or-
ganization, and steroid biosynthesis. Collectively, our
data indicate that PPAR-; activation by selective
agonists is a valid strategy for ovarian cancer therapy
and prevention, and should be tested alone and in
combination with other anticancer drugs.
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Introduction
Peroxisome proliferator–activated receptors (PPARs) are
members of the nuclear hormone receptor superfamily that
includes several ligand-activated transcription factors in-
volved in a variety of physiological and pathological pro-
cesses [1]. The PPAR subfamily consists of three closely
related receptors, namely a, b/y, and g, which regulatemeta-
bolic, developmental, and differentiation pathways [1].
PPARs play important roles in pathological conditions, such
as diabetes, atherosclerosis, and chronic inflammation, and are
seen as valid therapeutic targets in a variety of human diseases
[1]. PPAR-a is involved mainly in fatty acid metabolism and
transport [1]. High-affinity ligands of this receptor, such as
fenofibrate and bezafibrate, are effective hypolipidemic drugs
[1]. PPAR-g controls adipocyte differentiation, glucose metab-
olism, and lipid homeostasis, and synthetic PPAR-g agonists,
such as rosiglitazone and pioglitazone, are used as antidiabetic
drugs [2]. PPAR-y, which is the least studied of the three
subtypes, is ubiquitously expressed and plays a role in choles-
terol and lipid metabolism and in wound healing [3,4].
PPARs have the typical structure of nuclear hormone recep-
tors with DNA-binding, ligand-binding, and transactivation
domains [5]. PPARs form heterodimers with 9-cis retinoic acid
receptor (RXR) and bind to specific peroxisome proliferator–
activated receptor response elements (PPREs) in the promoter
region of target genes [5]. PPARs bind a diverse group of
lipophilic molecules, including long-chain fatty acids, prosta-
glandins, and leukotrienes [6,7]. Subtle changes in the ligand-
binding pocket of each isotype confer distinct ligand specificity
[8]. Ligand binding induces conformational remodeling, expos-
ing regions of the receptor needed for interaction with coac-
tivator molecules and for transactivation [8]. PPARs can
regulate transcription by additional mechanisms leading to
transrepression, instead of transactivation [9]. This aspect adds
another level of complexity to the study of PPAR functions in
physiological and pathological conditions.
In addition to their role in lipid and glucose metabolism,
PPARs play a role in cancer development and represent
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promising targets for novel cancer prevention and treatment
strategies [10,11]. Numerous studies have suggested that
PPAR-g may act as a tumor suppressor at least in some tis-
sues and cellular contexts [12]. Inactivating mutations, ge-
netic deletions, or chromosomal translocations leading to
functional inactivation of PPAR-g have been detected in
cancers of the colon, prostate, and thyroid [12–14]. Natural
and synthetic PPAR-g ligands, such as thiazolidinediones
and 15-deoxy-D12,14-prostaglandin J2, induce the growth
arrest and death of transformed cells in vitro [11,12,15–19].
PPAR-g ligands inhibit the growth of human tumor xeno-
grafts in nude mice and reduce the frequency of sponta-
neous and carcinogen-induced preneoplastic and neoplastic
lesions in animals [11,12,15,20]. Few studies, however, have
reported an increase in the frequency of tumors in mice
treated with synthetic PPAR-g agonists [10,21,22]. PPAR-g
ligands have also been the subject of clinical investigations
showing some activity in patients with advanced liposarcoma
and prostate cancer [11,12,15,18].
Epithelial ovarian cancer (EOC) is the most lethal gyne-
cologic cancer in Western countries, accounting for more
deaths than endometrial and cervical cancer deaths com-
bined [23]. EOC derives from the malignant transformation of
the ovarian surface epithelium, which is contiguous with the
peritoneal mesothelium [24]. Ovarian cancer is frequently
diagnosed in advanced stages, with the disease spread in the
peritoneum through direct implantation [23]. In these condi-
tions, surgery is rarely curative, and postoperative chemo-
therapy is required [23]. Current therapies for advanced
ovarian cancer are clearly inadequate, and new agents are
needed for the treatment of this disease [23,24]. The objec-
tive of this study was to determine whether PPAR-g could be
a valid target for ovarian cancer therapy and prevention.
We evaluated the expression of this nuclear receptor in ovar-
ian tumors and examined the cellular and molecular con-
sequences of PPAR-g activation in ovarian cancer cells. Our
data suggest that selective PPAR-g agonists could be very
effective agents in ovarian cancer and should be tested alone
and in combination with other molecular-targeted agents or
cytotoxic drugs.
Materials and Methods
Cell Lines, Reporter Vectors, and Compounds
The ovarian cancer cell lines A2780, OVCAR3, OVCAR5,
OVCAR8, OVCAR432, SKOV3, and IGROV1 were main-
tained in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Invitrogen Life
Technologies, San Diego, CA). PREx3-tk-Luc reporter was
a gift of Dr. R. Evans (The Salk Institute for Biological Studies,
La Jolla, CA), and pRL-SV40 control vector was purchased
from Promega Corporation (Madison WI). Ciglitazone and
GW9662 were purchased from Alexis Corporation (Lau-
sanne, Switzerland). The compounds were dissolved in
DMSO at a concentration of 100 mM and were kept at
20jC. Drug dilutions were prepared in a tissue culture
medium for each experiment and used immediately.
Reverse Transcriptase–Polymerase Chain Reaction
(RT-PCR), Immunoblotting, and Immunohistochemistry
Cells (1  105 cells/ml) were plated in six-well plates and
treated with ciglitazone. RNA was extracted from control and
drug-treated cells using Trizol (Invitrogen Life Technologies).
Using the SuperScript One-Step system from Invitrogen Life
Technologies (see Table W1 for PCR primers and condi-
tions), RT-PCR was performed. PCR products were sepa-
rated on agarose gels, stained with ethidium bromide, and
visualized with AlphaImager 3400 (Alpha Innotech Corpora-
tion, San Leandro, CA). For immunoblotting, cells were lysed
in NP-40 lysis buffer (50mMTris–HCl, pH 7.4, 250mMNaCl,
5 mM EDTA, 0.1% NP-40, 10 mM sodium orthovanadate,
2 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin, and
50 mM sodium fluoride) for 30 minutes on ice. Gel electro-
phoresis and immunoblotting were performed as described
[25]. Antibodies against PPAR-g (H100 and E8), p53 (DO1),
c-myc (9E10), and survivin (FL-1452) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies
against p21 (DCS60), bax, caspase 3 (3G2), and PTENwere
purchased from Cell Signaling Technology (Danvers, MA).
Antibodies against cyclin D1 (G124-326) and a-tubulin were
purchased from Becton Dickinson AG (Basel, Switzerland)
and Calbiochem-Merck Biosciences (Darmstadt, Germany),
respectively. Peroxidase-conjugated secondary antibodies
and the Enhanced Chemiluminescence system were
obtained from Amersham Biosciences (Little Chalfont, Buck-
inghamshire, UK). Immunohistochemistry was performed
with a mouse monoclonal antibody (E8) for PPAR-g on
5-mm-thick sections obtained from paraffin blocks of normal
ovaries (4), benign tumors, and ovarian tumors (27), includ-
ing 3 benign tumors (i.e., 1 mucinous cystoadenoma and 2
Brenner tumors), 5 borderline tumors (i.e., 2 mucinous and
3 serous cystoadenomas), 14 surface epithelial carcinomas,
2 malignant mixed mu¨llerian tumors, and 2 granulosa cell
tumors. Antigen retrieval was performed by six cycles of
5 minutes each in a microwave in 10 mM citrate buffer
(pH 6.0). Tissue sections were incubated overnight with an
anti–PPAR-g antibody (H100) at a 1:200 dilution. The intensity
of PPAR-g staining was scored as: (1+) = faint; (2+) = mod-
erate; (3+) = intense. As negative control, the primary antibody
was substituted with nonimmune mouse serum. The speci-
ficity of the primary antibody was also tested using tissues
with or without known expressions of pertinent antigens.
Luciferase Reporter Gene Assay
Cells were plated in 48-well plates at a density of 5  104
cells/ml in RPMI 1640 with 10% charcoal-stripped serum
(HyClone, Logan, UT) and transfected with 200 ng of
PPREx3-tk-Luc reporter and 20 ng of pRL-SV40 vector using
Lipofectamine (Life Technologies, Inc., Gaithersburg, MD).
After incubating for 4 hours, the cells were washed and in-
cubated in amediumwith or without ciglitazone andGW9662.
Cells were harvested 18 hours later to measure Firefly and
Renilla luciferase activities using the Dual-Luciferase assay
system (Promega Corporation). Data were expressed as
percentages of luciferase activity in drug-treated cells, com-
pared to control cells.
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Cell Proliferation
Cells were seeded in 96-well plates at a density of 1.5 
104 to 2.0  104 cells/ml and treated with ciglitazone. The
number of viable cells was measured after 72 hours by a
colorimetric assay using 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) tetrazolium salt (Sigma
Aldrich, Steinheim, Germany), as described [25]. For colony-
forming assays, cells were plated at a low cell density
(500 cells/well) in six-well plates and treated with ciglitazone.
Colonies were stained with crystal violet and counted after 10
to 14 days [25]. Cell growth inhibition assays were performed
in triplicate and repeated at least thrice. Student’s t test was
performed to assess the statistical significance of differences
among treatment groups.
Cell Cycle and Apoptosis
Cells were treated with ciglitazone and harvested after
24 and 48 hours. Cell cycle distribution and percentage of
apoptotic cells were determined as described [25]. The de-
tection of apoptotic cells by flow cytometry and fluorescence
microscopy following Annexin V–propidium iodide or DAPI
staining, respectively, was performed as described [25,26].
Microarray Analysis
Cells were plated in tissue culture flasks and incubated
with or without 100 mM ciglitazone for 18 hours. Total RNA
was isolated using Trizol (Invitrogen Life Technologies) and
the RNAeasy purification kit (Qiagen, Hilden, Germany), as
described [26]. Three independent replicateswere performed
for each experimental group. Labeling and hybridization to
Affymetrix (Santa Clara, CA) U133A GeneChips, as well as
data collection, were performed as described [26]. Briefly, raw
signals were extracted with MAS 5.0 software (Affymetrix),
and further analysis was performed using the Bioconductor
statistical package (www.bioconductor.org). Expression
values were calculated from raw CEL files using robust
multiarray average (RMA) [26]. Transcripts with statistically
significant changes in expression between the two treatment
groups were identified using significance analysis of micro-
array (SAM) [27]. A cutoff value of D = 0.8 was chosen for this
analysis. Functional annotation was performed using DAVID
2.0 annotation tool (National Institute of Allergy and Infectious
Disease, Frederick, MD; http://david.niaid.nih.gov/david/
version2/index.htm) to identify Gene Ontology classes, and
KEGG and BIOCARTA pathways [28] among genes with a
z 1.5-fold change in expression between untreated and
treated cells. Among differentially expressed genes, 371
upregulated and 196 downregulated genes had unique
DAVID IDs. P < .01 was used for statistical significance.
Results
Expression of PPAR-g in Ovarian Cancer Cell Lines
and Tissue Specimens
Expression of PPAR-gwas examined in a panel of ovarian
cancer cell lines using RT-PCR and immunoblotting. PPAR-g
RNA was detected in all cell lines examined (Figure 1A).
Along with PPAR-g, most of the cell lines also expressed
variable levels of PPAR-y and PPAR-a. Immunoblotting con-
firmed the expression of PPAR-g in ovarian cancer cells
(Figure 1B). The activity of PPAR-g as ligand-dependent
transcriptional activator was measured in A2780, OVCAR5,
and OVCAR8 cells using a luciferase reporter containing
a PPRE derived from the acyl-CoA oxidase gene. In the
three cell lines examined, luciferase activity increased to a
similar extent on incubation with the selective agonist ciglita-
zone (Figure 1C).
Expression of PPAR-g was also examined in normal
ovaries and ovarian cancer specimens. PPAR-g immunore-
activity was not observed in normal ovaries, whereas positive
staining was seen in epithelial ovarian tumors (Figure 1D). As
shown in Table 1, PPAR-g positivity was more frequent
in malignant tumors (9 of 14; 64%) than in borderline (1 of
5; 20%) and benign (1 of 3; 33%) tumors. Staining was
predominantly nuclear, whereas only two cases showed
cytoplasmic staining. Intense and diffuse nuclear stainings
(score, 3+) were observed in high-grade (G3) serous carci-
noma and undifferentiated (G4) carcinoma. The frequency
and intensity of staining were similar in the four major
histologic types of EOC and did not change significantly with
tumor grade (Table 1).
PPAR-g Agonist Ciglitazone Inhibits the Growth of Ovarian
Cancer Cells
To examine the consequences of PPAR-g activation
in ovarian cancer cells, we exposed cells to increasing
concentrations of ciglitazone in the presence of serum-
supplemented medium, and we measured cell proliferation
and survival after 72 hours. Ciglitazone inhibited the growth
of ovarian cancer cells, with IC50 ranging from f30 to
z100 mM (Figure 2A). As reported for other cell types [29],
growth inhibition by ciglitazone was greater under low
serum conditions, with a two-fold to a five-fold increase in
activity (Figure 2B).
Synthetic PPAR-g agonists, such as thiazolidinediones,
are known to induce PPAR-g–independent effects that can
contribute to cell growth inhibition [11]. Thus, to ensure that
growth arrest induced by ciglitazone was a consequence of
PPAR-g activation, A2780 cells were incubated with ciglita-
zone in the presence or absence of the PPAR-g antagonist
GW9662. Ciglitazone-induced PPAR-g activity was blocked
by cotreatment with the PPAR-g antagonist GW9662 in
reporter assays (Figure 2C). When given along with ciglita-
zone, GW9662 was able to prevent effects on cell growth,
indicating that the activity of the ligand was largely dependent
on PPAR-g (Figure 2D).
Next, we assessed the effects of ciglitazone on the clono-
genic survival of ovarian cancer cells. A2780, OVCAR5, and
OVCAR8 cells were seeded at low cell density and exposed
to 100 mM ciglitazone until colonies were visible in untreated
control cells. Under these conditions, the colony-forming
ability of the three cell lines was inhibited by ciglitazone
(Figure 2E). Similar levels of inhibition were seen in A2780,
OVCAR5, and OVCAR8 cells, despite the difference ob-
served in short-term growth inhibition assays and consistent
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with the similar PPAR-g content and activity in the three
cell lines.
Ciglitazone Delays Cell Cycle Progression and Induces
Apoptosis in Ovarian Cancer Cells
To investigate the mechanisms underlying the anti-
proliferative effect of ciglitazone, we examined the cell cycle
distribution of A2780 cells treated with ciglitazone for 24 and
48 hours. Ciglitazone induced a dose-dependent G1 arrest
after 24 hours of treatment (Figure 3). Cells in G1 increased
from 59% in control cells to 69% and 79% at 50 and 100 mM
ciglitazone, respectively. There was a concomitant reduction
of cells in S phase from 29% in control samples to 19% and
10% at 50 and 100 mM ciglitazone, respectively, with no
change in the fraction of G2 cells. Minimal signs of apop-
tosis (i.e., cells with sub-G1 DNA content) were present in
ciglitazone-treated samples at 24 hours. An increase of the
fraction of sub-G1 cells was evident after 48 hours of incu-
bation with 100 mM ciglitazone (19%), compared to control
cells (0.4%). The presence of apoptotic cells was confirmed
by fluorescence microscopy following DAPI staining and by
flow cytometry following Annexin V–propidium iodide stain-
ing (data not shown).
Ciglitazone Induces Changes in Cell Cycle–Associated
and Apoptosis-Associated Proteins in A2780 Cells
The treatment of cancer cells with PPAR-g agonists has
been reported to alter the level of proteins involved in cell
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Figure 1. Expression of PPAR-c in ovarian cancer cell lines and tissue samples. (A) RT-PCR was performed to determine the expression of PPAR a, /d, and c in
ovarian cancer cells. (B) Immunoblotting analysis of PPAR-c protein level in human ovarian cancer cell lines. (C) A2780, OVCAR5, and OVCAR8 cells were
transfected with a PPAR-responsive reporter and incubated with or without ciglitazone (50 M) for 18 hours. Luciferase activity was measured with the Dual-
Luciferase assay system. Data were normalized for transfection efficiency using the pRL-SV40 control vector and are expressed as the mean ± SD of triplicate
samples. *P < .01 compared to control cells. Immunohistochemistry was performed on tissue sections of paraffin-embedded specimens using a mouse monoclonal
antibody against PPAR-c or nonimmune mouse serum as negative control: (D) normal ovaries; (E) well-differentiated ovarian serous carcinoma (G1, 1+); (F) poorly
differentiated ovarian serous carcinoma (G3, 3+); (G) negative control section of the specimen in (F) (DAB–hematoxylin,  200).
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cycle, proliferation, and survival [11,30]. Immunoblotting and
RT-PCR showed that proteins involved in the positive and
negative control of cell growth and survival were either down-
regulated or upregulated in ovarian cancer cells treated with
ciglitazone. Negative regulators of cell growth and survival,
such as p53, p21, bax, caspase 3, and PTEN,were increased
by ciglitazone (Figure 4A). The levels of survivin, cyclin D1,
and c-myc that have antiapoptotic and growth-promoting
functions decreased following treatment with ciglitazone.
Most of these effects were determined at the transcriptional
level, as indicated by measurements of PTEN, p21, and
cyclin D1 RNA by RT-PCR (Figure 4B).
Transcriptional Response to the PPAR-c Agonist
Ciglitazone
To further examine the transcriptional consequences of
PPAR-g activation, gene expression wasmonitored in control
and ciglitazone-treated A2780 cells using U133A Affymetrix
GeneChips that contained probes for f18,500 transcripts.
A short treatment time of 18 hours was chosen with the intent
to increase the likelihood of identifying direct transcriptional
targets of PPAR-g. Genes differentially expressed with
high statistical significance between the two experimental
groups were identified using SAM (Figure 4C). Many genes
were affected in response to ciglitazone, although the level of
upregulation and downregulation was generally modest,
consistent with other studies [31–33]. Overall, almost equal
numbers of transcripts were upregulated and downregulated
(835 and 721, respectively), confirming that PPAR-g can
both activate and repress transcription. Among the 677 tran-
scripts with a z 1.5-fold change, 436 were upregulated
and 241 were downregulated (Table W2, A and B). The top
40 genes upregulated and downregulated in response to
ciglitazone are shown in Table 2.
Functional annotation of the genes with a z 1.5-fold
change in expression was performed using DAVID [28] to
identify biologic process and molecular function categories
predominantly affected by PPAR-g activation. The analysis
showed clearly distinct distributions of biologic process and
molecular function classes between upregulated and down-
regulated genes (Table 3). Upregulated classes were pre-
dominantly associated with metabolic pathways, including
carboxylic acid, amino acid and protein metabolism, protein
modification and ubiquitination, and transport and secretory
pathways. Genes involved in cell proliferation, cell cycle, cell
organization, DNA metabolism, and replication were pre-
dominant among the downregulated genes, in agreement
with the major phenotypic effects induced by ciglitazone in
ovarian cancer cells (i.e., growth inhibition, cell cycle arrest,
and cell death). Genes involved in lipid, sterol, and steroid
metabolism and biosynthesis, as well as genes associated
with microtubule and cytoskeleton-based processes, were
also overrepresented among the downregulated genes.
Hydrolases, cytoskeleton components, and nucleotide-
binding proteins were the predominant molecular function
classes among downregulated genes (Table 3). Various
ligases and, in particular, ubiquitin–protein ligases were the
classes overrepresented among upregulated genes, with the
latter finding providing a plausible explanation for the effects
of PPAR-g agonists on protein ubiquitination and stability
[34]. The functional distinction between upregulated and
downregulated genes was also reflected in the major KEGG
pathways identified by DAVID. The cell cycle (P = 1.97 
103) and biosynthesis of steroids (P = 3.09 103) were the
most affected pathways among downregulated genes,
whereas the metabolic pathways (e.g., aminoacyl-tRNA syn-
thesis, P = 3.67  103; glutamate metabolism, P = 6.84 
103) were those affected with statistical relevance among
upregulated genes.
Discussion
EOC is the most lethal gynecologic cancer, with 5-year
survival rates of < 50% [23]. Long-term survival for patients
with stage III and IV cancers ranges from 30% to < 10% [23].
The etiology and pathogenesis of EOC are still poorly under-
stood, which hinders the development of new molecular-
targeted approaches for the therapy and prevention of this
disease [23,24]. EOC arises from surface epithelial cells that
constitute the peritoneal lining of the ovary [35]. Various
reproductive and environmental factors, including incessant
ovulation, hormonal stimulation, endometriosis, and expo-
sure to carcinogens, have been linked to the risk of develop-
ing EOC [24]. Ovulation involves repetitive wounding, repair,
cell proliferation, and tissue remodeling [24]. Many cytokines
and proinflammatory mediators, including prostaglandins
and eicosanoids with potential tumor-promoting activity, are
released during the process [24,36]. Endometriosis is also
Table 1. Expression of PPAR-g in Ovarian Tumor Specimens*.
Histology Cases (n) Positive Cases
n (%) n (Staining
Intensity)
Tumor type
Surface epithelial benign tumors 3 1 (33) 1 (1+)
Surface epithelial borderline tumors 5 1 (20) 1 (1+)
Surface epithelial malignant tumors 14 9 (64) 6 (1+); 3 (3+)
Mullerian mixed malignant tumors 2 0 (0) –
Granulosa cell tumors 3 0 (0) –
Total 27 11 (41) 8 (1+); 3 (3+)
Gradey
1 2 2 1 (1+); 1 (3+)
2 3 2 2 (1+)
3 7 3 2 (1+); 1 (3+)
4 2 2 1 (1+); 1 (3+)
Total 14 9
Histologic typey
Serous 7 4 3 (1+); 1 (3+)
Mucinous 2 1 1 (1+)
Endometrioid 3 2 1 (1+); 1 (3+)
Undifferentiated 2 2 1 (1+); 1 (3+)
Total 14 9
*Immmunohistochemistry was performed on tissue sections cut from paraffin-
embedded specimens using a mouse monoclonal antibody against PPAR-g.
Staining intensity was scored as (1+) = faint, (2+) = moderate, and (3+) =
intense.
yGrade and histologic type distribution refer to surface epithelial carci-
nomas only.
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associated with the aberrant production of cytokines, growth
factors, and hormones that may promote the development of
ovarian cancer [11,24,36,37]. Steroid hormones and gona-
dotropins contribute to the growth of EOC because of their
mutagenic and tumor-promoting properties [24]. Environ-
mental carcinogens, such as talc and asbestos, are muta-
genic and stimulate the production of proinflammatory and
tumorigenic factors [24,36]. Thus, hormonal, inflammatory,
andmutagenic factors can create an environment of aberrant
endocrine, paracrine, and autocrine stimulation that upregu-
lates survival and proliferation signals in epithelial ovarian
cells favoring their transformation and expansion. At the
molecular level, partially distinct genetic alterations have
been associatedwithmajor histologic types of EOC, including
K-Ras and B-Rafmutations in low-grade serous carcinomas,
PTEN and K-Ras alterations in endometrioid carcinoma, and
p53 mutations, along with BRCA1, BRCA2, and Her-2 dys-
functions, in high-grade serous carcinoma [35,38,39]. Over-
all, alterations of several oncogenes and tumor-suppressor
genes, with consequent activation of survival and prolifera-
tion pathways, such as the Ras/Raf/MAPK and PI3K/Akt
pathways, underlie the development of EOC [38,40].
Given the current understanding of the pathogenesis of
EOC, PPAR-g seems an interesting target for the develop-
ment of novel therapeutic strategies for this disease. PPAR-g
agonists exhibit anticancer activity, inducing growth arrest
and death in a variety of cancer cell types [11,12,15]. PPAR-g
ligands also have anti-inflammatory and antiangiogenic prop-
erties that can contribute to their antitumor effect [41,42].
PPAR-g, along with other nuclear hormone receptors, in-
cluding estrogen, progesterone, androgen, retinoid, and vi-
tamin D receptors, is expressed in the normal ovaries [43].
Expression of PPAR-g is restricted to granulosa cells of
developing follicles and, after a transient increase, is down-
regulated in response to the increase of luteinizing hor-
mone after ovulation [43,44]. PPAR-g has been implicated
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Figure 2. Inhibition of ovarian cancer cell growth by ciglitazone. (A) Cells were incubated with ciglitazone, and cell survival was measured by a colorimetric (MTT)
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After 10 to 14 days, colonies were stained with crystal violet and counted. Data in the lower panels are presented as percentages of the number of colonies compared
to control cells (B, D, and E) and ciglitazone-treated cells (C). *P < .01 compared to ciglitazone-treated cells.
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Figure 3. Effects of ciglitazone on cell cycle distribution. A2780 cells were incubated with 50 and 100 M ciglitazone for 24 and 48 hours. Cells were fixed, stained
with propidium iodide, and analyzed by flow cytometry. The percentages of G1, G2, S, and sub-G1 cells are indicated in each panel.
Figure 4. Changes in gene expression induced by ciglitazone in ovarian cancer cells. (A) A2780 cells were incubated with 50 and 100 M ciglitazone for 24 and
48 hours. Cell lysates were prepared and analyzed by immunoblotting with specific antibodies. (B) PTEN, p21, and cyclin D1 RNA were measured in control and
ciglitazone-treated cells by RT-PCR. (C) A2780 cells were incubated with 100 M ciglitazone for 18 hours before microarray analysis. Differentially expressed
genes were identified according to SAM. Observed differences in the expression of each individual transcript were plotted against expected differences. The
diagonal solid line indicates the point where observed and expected differences are equal. A value of D = 0.8, indicated by the position of the two diagonal dotted
lines relative to the diagonal solid line, was chosen as cutoff. Circles above and below the horizontal dotted lines are transcripts with a statistically significant
difference in expression between ciglitazone-treated and untreated cells.
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in various aspects of ovarian physiology, including ovulation,
tissue remodeling, and response to hormonal stimulation
[43]. Although the mechanisms are not fully understood, this
nuclear receptor has the potential to control the expression of
various genes, including those involved in steroidogenesis
(e.g., aromatase), inflammation (e.g., cyclooxygenase-2 and
nitric oxide synthase), tissue remodeling (e.g., matrix
metalloproteases), and angiogenesis (e.g., vascular endo-
thelial growth factor), which could be required for follicle
development, ovulation, and maintenance of the corpus
luteum [43,44]. Interestingly, PPAR-g haploinsufficiency
increases the frequency of carcinogen-induced ovarian
cancer in PPAR-g+/ mice compared to wild-type mice, sug-
gesting that PPAR-g might also provide a protective effect
against ovarian cancer development [45]. We found that
PPAR-gwas expressed, albeit at low levels, in a large fraction
of EOC and in all the ovarian cancer cell lines tested. There
was no staining for PPAR-g in the surface epithelium and
cortical stroma of normal ovary specimens, as shown in a
previous study [46] and in agreement with the restricted
expression of PPAR-g to granulosa cells in developing ovar-
ian follicles [43,44]. The expression of PPAR-g in human
ovarian cancer was also reported in two other recent studies
that showed moderate immunohistochemical staining for
Table 2. Genes Differentially Expressed in Ciglitazone-Treated Ovarian
Cancer Cells*.
Gene Symbol Gene Title Fold
Change
(A) Upregulated
SLC7A11 Solute carrier family 7, member 11 5.73
STCH Stress 70 protein chaperone 4.43
SEC31L1 SEC31-like 1 3.55
C1orf24 Chromosome 1 open reading frame 24 3.37
ATF3 Activating transcription factor 3 3.35
EPRS Glutamyl-prolyl-tRNA synthetase 3.20
VLDLR Very-low-density lipoprotein receptor 3.13
ROCK1 Rho-associated, coiled coil – containing
protein kinase 1
3.11
IFRD1 Interferon-related developmental
regulator 1
3.10
TRIM2 Tripartite motif –containing 2 2.99
DSIPI Delta sleep-inducing peptide 2.96
BCAT1 Branched-chain aminotransferase 1 2.74
DDIT4 DNA damage– inducible transcript 4 2.73
CLCN3 Chloride channel 3 2.71
COPA Coatomer protein complex, subunit a 2.70
DDIT3 DNA damage– inducible transcript 3 2.69
POLI Polymerase (DNA-directed) L 2.68
GDF15 Growth differentiation factor 15 2.67
KIAA0776 KIAA0776 2.64
D2LIC Dynein 2 light intermediate chain 2.59
P8 p8 protein 2.56
RSN Restin 2.56
INHBE Inhibin, b E 2.56
KIAA0436 Putative prolyl oligopeptidase 2.53
PTPN13 Protein tyrosine phosphatase,
nonreceptor type 13
2.52
DNAJB9 DnaJ (Hsp40) homolog, subfamily B,
member 9
2.52
FLJ21657 Hypothetical protein FLJ21657 2.52
NEBL Nebulette 2.48
PFAAP5 Phosphonoformate-immunoassociated
protein 5
2.47
CSAD Cysteine sulfinic acid decarboxylase 2.46
CEBPB CCAAT/enhancer binding protein b 2.42
CEBPG CCAAT/enhancer binding protein g 2.42
NARG2 NMDA receptor – regulated gene 2 2.42
PSAT1 Phosphoserine aminotransferase 1 2.41
FLJ11273 Hypothetical protein FLJ11273 2.39
NAP1L3 Nucleosome assembly protein
1– like 3
2.38
DAF Decay-accelerating factor for
complement
2.36
TRIB3 Tribbles homolog 3 2.36
ASNS Asparagine synthetase 2.35
FLJ14007 Hypothetical protein FLJ14007 07 2.34
(B) Downregulated
TUBB4 Tubulin, b, 4 2.58
INSIG1 Insulin-induced gene 1 2.53
TUBB2 Tubulin, b, 2 2.51
ADM Adrenomedullin 2.36
RGC32 Response gene to complement 32 2.33
PHLDA2 Leckstrin homology– like domain,
family A, member 2
2.15
EFHD2 EF hand domain containing 2 2.07
RAC3 Ras-related C3 Botulinum toxin
substrate 3
2.04
H2AFX H2A histone family, member X 2.03
DBP D site of albumin promoter binding
protein
2.01
TBX2 T-box 2 2.00
LMNB2 Lamin B2 2.00
ASF1B ASF1 antisilencing function 1
homolog B
1.99
PA2G4 Proliferation-associated 2G4, 38 kDa 1.97
UBE2L3 Ubiquitin-conjugating enzyme E2L 3 1.95
EMP1 Epithelial membrane protein 1 1.95
Table 2. (continued )
Gene Symbol Gene Title Fold
Change
(B) Downregulated
GPRC5B G protein–coupled receptor, family C,
group 5, member B
1.94
MRPS12 Mitochondrial ribosomal protein S12 1.94
FHOD1 Formin homology 2 domain–
containing 1
1.93
IFIT1 Interferon-induced protein with
tetratricopeptide repeats 1
1.92
SPHK1 Sphingosine kinase 1 1.92
NOTCH3 Notch homolog 3 1.91
CDC25A Cell division cycle 25A 1.90
TWIST1 Twist homolog 1 1.87
ACAT2 Acetyl-coenzyme A acetyltransferase 2 1.87
MLP MARCKS-like protein 1.86
MICB MHC class I polypeptide– related
sequence B
1.85
FKBP4 FK506-binding protein 4, 59 kDa 1.85
NR4A2 Nuclear receptor subfamily 4, group A,
member 2
1.84
NRGN Neurogranin 1.84
HSPB1 Heat shock 27-kDa protein 1 1.83
FDPS Farnesyl diphosphate synthase
(geranyl transferase)
1.83
FSCN1 Fascin homolog 1, actin-bundling
protein
1.82
IGFBP4 Insulin-like growth factor –binding
protein 4
1.81
FLJ23311 FLJ23311 protein 1.81
TCF3 Transcription factor 3 1.81
LDLR Low-density lipoprotein receptor 1.80
GP1BB Glycoprotein Ib (platelet), b polypeptide 1.80
SERPINB9 Serine (or cysteine) proteinase
inhibitor, member 9
1.79
EXOSC4 Exosome component 4 1.79
*Differentially expressed genes were identified using SAM. The first 40 genes
with the highest increase or decrease in expression are listed. A complete list
is provided in the supplemental material (Table W2, A and B).
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PPAR-g in malignant, borderline, and benign ovarian tumors
[46,47]. Due to the size of these studies, it is difficult to
establish whether the frequency and level of expression of
PPAR-g vary between benign, borderline, and malignant
tumors. Furthermore, the level of PPAR-g RNA and proteins
in tumor cells may not correspond to the level of activity of the
receptor, which is strongly regulated posttranscriptionally
[12]. For example, the increased PPAR-g level in Her-2–
overexpressing breast cancer cells was associated with
reduced transcriptional activity and ligand-induced growth
inhibition [48]. It is likely that similar genetic alterations and
consequent activation of signaling pathways, such as Ras/
Raf/MAPK and PI3K/Akt, lead to the functional down-
regulation of PPAR-g in EOC.
Cellular consequences of PPAR-g activation may vary in
different cell types [11,12,15]. Early reports of growth arrest,
differentiation, and cell death in cancer cells as a result of
PPAR-g activation with synthetic and natural agonists have
been widely confirmed [11,15]. However, natural and syn-
thetic agonists, such as thiazolidinediones, also have PPAR-
g–independent effects [11]. Therefore, one must be cautious
in interpreting data on this class of compounds. In our study,
the growth of ovarian cancer cells was inhibited by the PPAR-
g agonist ciglitazone in a dose-dependent manner in both cell
viability and colony-forming assays. The antiproliferative
effect of ciglitazone was reversed by coincubation with the
PPAR-g antagonist GW9662, suggesting that the ligand
acted mainly through PPAR-g–dependent mechanisms.
Growth inhibition by ciglitazone was associated with changes
in cell cycle distribution in ovarian cancer cells, with an in-
creased proportion of cells in the G1 phase and a reduction
of S-phase cells within 24 hours of treatment. This was
Table 3. Biologic Process and Molecular Function Classes Preferentially
Affected by Ciglitazone in Ovarian Cancer Cells*.
Class Genes P
(A) Upregulated genes
Biologic process
Macromolecule metabolism 98 2.70E8
Golgi vesicle transport 11 4.71E8
Protein transport 26 5.87E8
Carboxylic acid metabolism 25 7.95E8
Organic acid metabolism 25 8.73E8
Metabolism 173 8.76E8
Amine metabolism 21 2.14E7
Vesicle-mediated transport 20 5.41E7
Amino acid metabolism 17 1.8E6
Secretory pathway 13 1.32E6
Protein metabolism 80 1.66E6
ER to Golgi transport 7 1.71E6
Amino acid and derivative metabolism 18 2.25E6
Intracellular transport 22 1.10E5
Protein modification 43 3.18E4
Cell growth and/or maintenance 92 3.38E4
Biosynthesis 36 4.95E4
tRNA modification 7 6.3E4
Intracellular protein transport 14 7.83E4
tRNA metabolism 8 1.26E3
RNA modification 7 1.43E3
Ubiquitin cycle 16 1.61E3
Amino acid activation 6 2.48E3
tRNA aminoacylation 6 2.48E3
tRNA aminoacylation for protein translation 6 2.48E3
Protein ubiquitination 13 2.87E3
Cellular physiological process 98 2.87E3
Amine biosynthesis 6 3.12E3
Amino acid biosynthesis 5 3.36E3
Physiological process 231 5.88E3
Serine family amino acid metabolism 4 9.24E3
Molecular function
Ligase activity 29 8.94E9
Catalytic activity 124 3.3E5
Ligase activity, forming carbon–nitrogen bonds 19 8.77E5
Ubiquitin –protein ligase activity 16 4.34E4
Ligase activity, forming phosphoric ester bonds 7 5.29E4
Ligase activity, forming carbon–oxygen bonds 6 1.97E3
tRNA ligase activity 6 1.97E3
Transaminase activity 5 2.69E3
Transferase activity, transferring nitrogenous 5 2.96E3
Purine nucleotide binding 40 6.43E3
Intracellular transporter activity 4 8.90E3
Nucleotide binding 40 9.9E3
(B) Downregulated genes
Biologic process
Cell proliferation 48 1.14E16
Cell cycle 38 1.15E14
Regulation of cell cycle 25 6.75E12
Cellular physiological process 87 1.13E10
Cell growth and/or maintenance 79 2.65E10
Cell organization and biogenesis 27 1.15E7
DNA metabolism 24 1.48E7
Mitotic cell cycle 14 1.99E7
Steroid biosynthesis 9 4.24E7
Microtubule polymerization 6 1.24E6
Cellular process 105 1.62E6
Steroid metabolism 11 1.91E6
Cholesterol metabolism 8 3.34E6
Cholesterol biosynthesis 6 3.46E6
Sterol metabolism 8 5.70E6
Sterol biosynthesis 6 8.2E6
Lipid biosynthesis 11 1.92E5
G1/S transition of mitotic cell cycle 7 2.31E5
DNA replication 11 1.6E4
Microtubule-based process 8 1.41E4
Cytoskeleton-dependent intracellular transport 6 1.73E4
Microtubule-based movement 6 1.73E4
Alcohol metabolism 11 3.76E4
Table 3. (continued )
Class Genes P
(B) Downregulated genes
Biologic process
Nucleobase, nucleoside, and nucleotide 52 5.59E4
Lipid metabolism 16 7.79E4
DNA-dependent DNA replication 6 1.80E3
DNA replication initiation 4 1.96E3
Cell growth 7 2.40E3
Regulation of cell size 7 2.40E3
Chromosome organization and biogenesis 9 3.14E3
Cytoskeleton organization and biogenesis 10 3.49E3
Nuclear organization and biogenesis 9 3.49E3
Cytoplasm organization and biogenesis 12 3.75E3
Development 32 4.17E3
Growth 7 7.27E3
Cellular morphogenesis 7 8.55E3
Molecular function
Protein binding 38 2.50E5
GTPase activity 9 7.77E5
Hydrolase activity, phosphorus-containing 15 3.29E4
Hydrolase activity, acid anhydrides 15 8.57E4
Structural constituent of cytoskeleton 6 3.1E3
Structural –molecular activity 17 3.7E3
Purine nucleotide binding 27 3.72E3
Nucleotide binding 27 4.95E3
Cytoskeletal protein binding 9 6.24E3
*Using DAVID, functional annotation was performed on the upregulated and
downregulated genes with unique DAVID IDs and a z 1.5-fold change in
expression. Only classes with P < .01 are shown.
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followed at later times by induction of cell death. Interestingly,
a more prominent antiproliferative and apoptotic effect
was observed when cells were treated under low serum
conditions, suggesting that PPAR-g agonists might be par-
ticularly effective in combination with agents mimicking
growth factor deprivation or similar stress conditions. In-
deed, the combination of PPAR-g agonists with a variety of
agents, including retinoids, cyclooxygenase-2, and growth
factor receptor inhibitors, has been tested recently, with
promising results [48–50].
Although the exact mechanism of PPAR-g–mediated
growth inhibition can be different in various cell types, it is
likely that this nuclear receptor induces its effects primarily
by modulating the expression of target genes that control
cell growth, differentiation, and survival [10,11]. PPAR-g can
regulate transcription by distinct mechanisms, including
ligand-dependent transactivation, ligand-dependent trans-
repression, and ligand-independent transrepression [51].
Ligand-dependent transactivation is due to the binding of
PPAR-g/RXR heterodimers to target genes and the recruit-
ment of coactivator complexes following ligand binding [51].
Conversely, PPAR-g can repress the transcription of genes
to which it is bound by actively recruiting transcriptional
corepressors in the absence of ligand [51]. The mechanism
involved in ligand-dependent transrepression is less under-
stood. This form of transcriptional repression does not in-
volve the binding of PPAR-g to PPRE in negatively regulated
genes, but may require binding to and inhibition of other
transcription factors, such as AP1, STAT, and NF-nB [51].
Accordingly, transcriptional responses to PPAR-g activation
can be highly complex. Despite this, only a few studies have
employed methods of global gene expression analysis to
examine the impact of PPAR-g activation on the transcrip-
tional program of cancer cells [31,33]. As indicated by our
microarray study, the expression of several genes was mod-
ulated either positively or negatively by ciglitazone in ovarian
cancer cells, indicating that both transactivation and trans-
repression can play an important role in the antitumor ef-
fect of PPAR-g agonists. Growth inhibition by the PPAR-g
agonist was likely the combined result of the activation of
antiproliferative and tumor-suppressor pathways (e.g., p53,
p21, and PTEN) and the inhibition of growth-promoting path-
ways (e.g., cyclin D1 and c-myc). A number of apoptosis-
associated genes, such as bax, caspase-3, and survivin,
were also affected by ciglitazone, suggesting that these
changes might contribute to the overall antitumor effect.
Similar changes in cell cycle–associated and apoptosis-
associated genes have been reported in other cell types
[11,30]. The activation of p53-dependent pathways could be
an important event in cells with p53wt, such as A2780 cells.
However, cells with deleted or mutated p53 (e.g., SKVO3 and
clones of A2780 cells with p53mut; Figure 2 and data not
shown) were equally sensitive to ciglitazone, suggesting that
p53was not the only factor involved in growth inhibition by the
PPAR-g agonist. Furthermore, p53-regulated genes, such as
p21, can be activated by alternative mechanisms in response
to PPAR-g ligands and, thus, their upregulation cannot be
taken as a definitive marker of p53-mediated response [52].
Our microarray-based gene profiling study also showed that
PPAR-g activation induced pleiotropic effects on the tran-
scriptional program of ovarian cancer cells, involving meta-
bolic (e.g., amino acid and lipid metabolism), hormonal (e.g.,
sterol and steroid biosynthesis), cell organization, and regu-
latory (e.g., cytoskeletal proteins and ubiquitin–protein
ligases) pathways, and raising the possibility that these
additional mechanisms might contribute to the antitumor
activity of nuclear receptor agonists, perhaps in a tumor-
specific and tissue-specific manner.
Overall, our data indicate that PPAR-g agonists can
interfere with cell-autonomous and nonautonomous signal-
ing pathways regulating the cell growth and survival of EOC
cells. Metabolic effects, anti-inflammatory properties, and
antiangiogenic properties of this type of compounds can
contribute to antitumor activity by affecting the paracrine
and endocrine pathways, sustaining the development of
ovarian cancer. Our preclinical data support further studies
of selective PPAR-g agonists alone and in combination with
other molecular-targeted agents or cytotoxic drugs for the
treatment of ovarian cancer. The efficacy of such strategies
should be tested first in appropriate animal models, particu-
larly in consideration of some contradictory results observed
in some murine models [10,21,22].
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Table W1. Primers and PCR Conditions.
Gene Forward (F) and Reverse (R) Primers PCR cycles
PPARc F 5V-TCTGGCCCACCAACTTTGGG-3V 15 sec at 94jC
R 5V-CTTCACAAGCATGAACTCCA-3V 30 sec at 60jC
45 sec at 72jC
30 cycles
PPARd F 5V-GGCCTTCTCCAAGCACATCTA-3V 15 sec at 94jC
R 5V-TGCGCAGGAACTCACGGGTGA-3V 30 sec at 59jC
45 sec at 72jC
30 cycles
PPARa F 5V-GGACGATCTCCACAGCAAAT- 3V 30 sec at 94jC
R 5V-ATGGCATCCAGAACAAGGAG-3V 30 sec at 53jC
30 sec at 72jC
30 cycles
PTEN F 5V-CTCCAATTCAGGACCCACACGAC-3V 15 sec at 94jC
R 5V-CCTCTGGATTTGACGGCTCCT-3V 30 sec at 55jC
60 sec at 72jC
24 cycles
p21 F 5V-GGAAGACCATGTGGACCTGT-3V 30 sec at 94jC
R 5V-GCCAGGGTATGTACATGAGGA-3V 30 sec at 57jC
30 sec at 72jC
28 cycles
Cyclin D1 F 5V-CTCCTGTGCTGCGAAGTGGA-3V 15 sec at 94jC
R 5V-CCGGATGGAGTTGTCGGTGT-3V 30 sec at 60jC
45 sec at 72jC
28 cycles
GAPDH F 5V-CGGCTACTAGCGGTTTTACG-3V 15 sec at 94jC
R 5V-AAGAAGATGCGGCTGACTGT-3V 30 sec at 55jC
30 sec at 72jC
21 cycles
TableE W2-A. SAM Analysis of Differentially Expressed Genes: Upregulated Genes.
Gene Symbol Fold change Gene Title
SLC7A11 5.73 Solute carrier family 7, (cationic amino acid transporter, y+ system) member 11
STCH 4.43 Stress 70 protein chaperone, microsome-associated, 60kDa
SLC7A11 4.37 Solute carrier family 7, (cationic amino acid transporter, y+ system) member 11
SEC31L1 3.55 SEC31-like 1 (S. cerevisiae)
C1orf24 3.37 Chromosome 1 open reading frame 24
ATF3 3.35 Activating transcription factor 3
EPRS 3.20 Glutamyl-prolyl-tRNA synthetase
VLDLR 3.13 Very low density lipoprotein receptor
ROCK1 3.11 Rho-associated, coiled-coil containing protein kinase 1
IFRD1 3.10 Interferon-related developmental regulator 1
TRIM2 2.99 Tripartite motif-containing 2
DSIPI 2.96 Delta sleep inducing peptide, immunoreactor
BCAT1 2.74 Branched chain aminotransferase 1, cytosolic
DDIT4 2.73 DNA-damage-inducible transcript 4
IFRD1 2.72 Interferon-related developmental regulator 1
CLCN3 2.71 Chloride channel 3
COPA 2.70 Coatomer protein complex, subunit alpha
DDIT3 2.69 DNA-damage-inducible transcript 3
POLI 2.68 Polymerase (DNA directed) iota
GDF15 2.67 Growth differentiation factor 15
KIAA0776 2.64 KIAA0776
D2LIC 2.59 Dynein 2 light intermediate chain
P8 2.56 P8 protein (candidate of metastasis 1)
RSN 2.56 Restin (Reed-Steinberg cell-expressed intermediate filament-associated protein)
INHBE 2.56 Inhibin, beta E
KIAA0436 2.53 Putative prolyl oligopeptidase
PTPN13 2.52 Protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95
(Fas)-associated phosphatase)
DNAJB9 2.52 DnaJ (Hsp40) homolog, subfamily B, member 9
FLJ21657 2.52 Hypothetical protein FLJ21657
STCH 2.52 Stress 70 protein chaperone, microsome-associated, 60kDa
CLCN3 2.48 Chloride channel 3
NEBL 2.48 Nebulette
PFAAP5 2.47 Phosphonoformate immuno-associated protein 5
CSAD 2.46 Cysteine sulfinic acid decarboxylase
EPRS 2.45 Glutamyl-prolyl-tRNA synthetase
CEBPB 2.42 CCAAT/enhancer binding protein (C/EBP), beta
CEBPG 2.42 CCAAT/enhancer binding protein (C/EBP), gamma
NARG2 2.42 NMDA receptor-regulated gene 2
PSAT1 2.41 Phosphoserine aminotransferase 1
FLJ11273 2.39 Hypothetical protein FLJ11273
NAP1L3 2.38 Nucleosome assembly protein 1-like 3
DAF 2.36 Decay accelerating factor for complement (CD55, Cromer blood group system)
TRIB3 2.36 Tribbles homolog 3 (Drosophila)
ASNS 2.35 Asparagine synthetase
FLJ14007 2.34 Hypothetical protein FLJ14007
EIF2AK3 2.33 Eukaryotic translation initiation factor 2-alpha kinase 3
PGM3 2.31 Phosphoglucomutase 3
RHOB 2.30 Ras homolog gene family, member B
SLC1A4 2.30 Solute carrier family 1 (glutamate/neutral amino acid transporter), member 4
IMPACT 2.29 Hypothetical protein IMPACT
GFPT1 2.28 Glutamine-fructose-6-phosphate transaminase 1
PJA2 2.26 Praja 2, RING-H2 motif containing
PFAAP5 2.25 Phosphonoformate immuno-associated protein 5
CCPG1 2.23 Cell cycle progression 1
SLC31A1 2.22 Solute carrier family 31 (copper transporters), member 1
FLJ13096 2.21 Hypothetical protein FLJ13096
HNRPD 2.21 Heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding
protein 1, 37kDa)
PCK2 2.20 Phosphoenolpyruvate carboxykinase 2 (mitochondrial)
DAAM1 2.20 Dishevelled associated activator of morphogenesis 1
LOC51315 2.19 Hypothetical protein LOC51315
COG5 2.19 Component of oligomeric golgi complex 5
SH3YL1 2.18 SH3 domain containing, Ysc84-like 1 (S. cerevisiae)
RTCD1 2.16 RNA terminal phosphate cyclase domain 1
DNAJC10 2.16 DnaJ (Hsp40) homolog, subfamily C, member 10
FLJ10074 2.13 Hypothetical protein FLJ10074
SIP1 2.13 Survival of motor neuron protein interacting protein 1
KIAA0436 2.13 Putative prolyl oligopeptidase
FNDC3 2.12 Fibronectin type III domain containing 3
DNAJC10 2.12 DnaJ (Hsp40) homolog, subfamily C, member 10
BTG1 2.10 B-cell translocation gene 1, anti-proliferative
SLC1A4 2.09 Solute carrier family 1 (glutamate/neutral amino acid transporter), member 4
PMAIP1 2.09 Phorbol-12-myristate-13-acetate-induced protein 1
Table W2-A. (continued )
Gene Symbol Fold change Gene Title
CDC42BPA 2.08 CDC42 binding protein kinase alpha (DMPK-like)
DKFZP564A022 2.08 Hypothetical protein DKFZp564A022
CLIC4 2.07 Chloride intracellular channel 4
PIGK 2.07 Phosphatidylinositol glycan, class K
PEX1 2.06 Peroxisome biogenesis factor 1
SERP1 2.06 Stress-associated endoplasmic reticulum protein 1
MGC4504 2.06 Hypothetical protein MGC4504
EPS15 2.06 Epidermal growth factor receptor pathway substrate 15
SEC24D 2.05 SEC24 related gene family, member D (S. cerevisiae)
C6orf48 2.05 Chromosome 6 open reading frame 48
DNAJB9 2.05 DnaJ (Hsp40) homolog, subfamily B, member 9
RIPX 2.03 Rap2 interacting protein x
BLZF1 2.03 Basic leucine zipper nuclear factor 1 (JEM-1)
BET1 2.02 BET1 homolog (S. cerevisiae)
FLJ21439 2.02 Hypothetical protein FLJ21439
PTPN4 2.02 Protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)
CCNB1IP1 2.02 Cyclin B1 interacting protein 1
ANKRA2 2.01 Ankyrin repeat, family A (RFXANK-like), 2
WARS 2.00 Tryptophanyl-tRNA synthetase
SRP72 1.99 Signal recognition particle 72kDa
MAP1B 1.99 Microtubule-associated protein 1B
WSB1 1.98 WD repeat and SOCS box-containing 1
LOC286148 1.97 Hypothetical protein LOC286148
VAMP4 1.97 Vesicle-associated membrane protein 4
DMTF1 1.97 Cyclin D binding myb-like transcription factor 1
KIAA0776 1.97 KIAA0776
WARS 1.97 Tryptophanyl-tRNA synthetase
Ufm1 1.97 Ubiquitin-fold modifier 1
DAF 1.96 Decay accelerating factor for complement (CD55, Cromer blood group system)
SEC63 1.96 SEC63-like (S. cerevisiae)
C6orf75 1.96 Chromosome 6 open reading frame 75
STAM2 1.96 Signal transducing adaptor molecule (SH3 domain and ITAM motif) 2
SEC22L1 1.96 SEC22 vesicle trafficking protein-like 1 (S. cerevisiae)
CGI-109 1.95 CGI-109 protein
VRK2 1.95 Vaccinia related kinase 2
HERPUD1 1.94 Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like
domain member 1
CLIC4 1.94 Chloride intracellular channel 4
STX16 1.93 Syntaxin 16
D2LIC 1.92 Dynein 2 light intermediate chain
KIAA0092 1.92 Translokin
CAPN7 1.91 Calpain 7
RNF13 1.91 Ring finger protein 13
CLCN3 1.91 Chloride channel 3
CLCN3 1.90 Chloride channel 3
GOLGA5 1.90 Golgi autoantigen, golgin subfamily a, 5
RPS6KC1 1.90 Ribosomal protein S6 kinase, 52kDa, polypeptide 1
MINA 1.89 MYC induced nuclear antigen
SLC35A5 1.89 Solute carrier family 35, member A5
CASP4 1.89 Caspase 4, apoptosis-related cysteine protease
RIN2 1.89 Ras and Rab interactor 2
PP35 1.89 Protein similar to E.coli yhdg and R. capsulatus nifR3
ELOVL6 1.89 ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2,
SUR4/Elo3-like, yeast)
SLC1A4 1.89 Solute carrier family 1 (glutamate/neutral amino acid transporter), member 4
KIAA0924 1.88 KIAA0924 protein
JUN 1.88 V-jun sarcoma virus 17 oncogene homolog (avian)
CHC1L 1.88 Chromosome condensation 1-like
ARMCX3 1.88 Armadillo repeat containing, X-linked 3
WDR11 1.88 WD repeat domain 11
PDE4D 1.88 Phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila)
KAT3 1.88 Kynurenine aminotransferase III
KIAA0888 1.87 KIAA0888 protein
TCEA1 1.87 Transcription elongation factor A (SII), 1
KIAA0092 1.87 Translokin
WIPI49 1.86 WD40 repeat protein Interacting with phosphoInositides of 49kDa
AP2B1 1.86 Adaptor-related protein complex 2, beta 1 subunit
DZIP1 1.85 DAZ interacting protein 1
SNAP23 1.85 Synaptosomal-associated protein, 23kDa
GOLGIN-67 1.85 Golgin-67
RIOK3 1.85 RIO kinase 3 (yeast) /// RIO kinase 3 (yeast)
EIF5 1.84 Eukaryotic translation initiation factor 5
LOC90410 1.83 Intraflagellar transport protein IFT20
HMOX1 1.83 Heme oxygenase (decycling) 1
Table W2-A. (continued )
Gene Symbol Fold change Gene Title
ZNF184 1.83 Zinc finger protein 184 (Kruppel-like)
ZCWCC2 1.83 Zinc finger, CW-type with coiled-coil domain 2
NDP52 1.83 Nuclear domain 10 protein
WSB1 1.83 WD repeat and SOCS box-containing 1
AGTPBP1 1.82 ATP/GTP binding protein 1
ARHGEF2 1.82 Rho/rac guanine nucleotide exchange factor (GEF) 2
USP14 1.82 Ubiquitin specific protease 14 (tRNA-guanine transglycosylase)
UBE2J1 1.82 Ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast)
STC2 1.82 Stanniocalcin 2
CCNT2 1.81 Cyclin T2
OGT 1.81 O-linked N-acetylglucosamine (GlcNAc) transferase
FAIM 1.81 Fas apoptotic inhibitory molecule
RAB5A 1.81 RAB5A, member RAS oncogene family
KIAA1641 1.80 KIAA1641
SERP1 1.80 Stress-associated endoplasmic reticulum protein 1
RCHY1 1.80 Ring finger and CHY zinc finger domain containing 1
SLC30A5 1.80 Solute carrier family 30 (zinc transporter), member 5
KIAA0092 1.79 Translokin
SMAP-5 1.79 Golgi membrane protein SB140
MOSPD1 1.79 Motile sperm domain containing 1
CLIC4 1.79 Chloride intracellular channel 4
ZNF131 1.79 Zinc finger protein 131 (clone pHZ-10)
C20orf36 1.79 Chromosome 20 open reading frame 36
COG5 1.79 Component of oligomeric golgi complex 5
MINA 1.79 MYC induced nuclear antigen
RHOQ 1.79 Ras homolog gene family, member Q
LOC137886 1.79 Hypothetical protein LOC137886
GFPT1 1.78 Glutamine-fructose-6-phosphate transaminase 1
SLC7A11 1.78 Solute carrier family 7, (cationic amino acid transporter, y+ system) member 11
PEX1 1.78 Peroxisome biogenesis factor 1
C9orf95 1.78 Chromosome 9 open reading frame 95
CAST 1.77 Calpastatin
C8orf2 1.77 Chromosome 8 open reading frame 2
FKBP1B 1.77 FK506 binding protein 1B, 12.6 kDa
RHOQ 1.77 Ras homolog gene family, member Q
SCAMP1 1.76 Secretory carrier membrane protein 1
MTMR6 1.76 Myotubularin related protein 6
FLJ11200 1.76 Hypothetical protein FLJ11200
ZNF23 1.76 Zinc finger protein 23 (KOX 16)
TCF12 1.76 Transcription factor 12 (HTF4, helix-loop-helix transcription factors 4)
ARL1 1.75 ADP-ribosylation factor-like 1
AD-017 1.75 Glycosyltransferase AD-017
MYST4 1.75 MYST histone acetyltransferase (monocytic leukemia) 4
CALU 1.75 Calumenin
NPL 1.75 N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase)
FTS 1.74 Fused toes homolog (mouse)
SEC24D 1.74 SEC24 related gene family, member D (S. cerevisiae)
EFHC1 1.74 EF-hand domain (C-terminal) containing 1
EXOSC8 1.74 Exosome component 8
FLJ11336 1.74 Hypothetical protein FLJ11336
PDE4DIP 1.74 Phosphodiesterase 4D interacting protein (myomegalin)
FEM1B 1.74 Fem-1 homolog b (C. elegans)
PHKB 1.74 Phosphorylase kinase, beta
RAB5A 1.73 RAB5A, member RAS oncogene family
NGLY1 1.73 N-glycanase 1
RIOK3 1.73 RIO kinase 3 (yeast)
HSPA5 1.73 Heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)
GADD45A 1.73 Growth arrest and DNA-damage-inducible, alpha
PRSS16 1.73 Protease, serine, 16 (thymus)
ORC4L 1.73 Origin recognition complex, subunit 4-like (yeast)
ME1 1.72 Malic enzyme 1, NADP(+)-dependent, cytosolic
M17S2 1.72 Membrane component, chromosome 17, surface marker 2 (ovarian carcinoma
antigen CA125)
FBXO3 1.71 F-box protein 3
ZFR 1.71 Zinc finger RNA binding protein
MSH5 1.71 MutS homolog 5 (E. coli)
CXorf45 1.71 Chromosome X open reading frame 45
SLC24A1 1.71 Solute carrier family 24 (sodium/potassium/calcium exchanger), member 1
MCLC 1.71 Mid-1-related chloride channel 1
SEC23A 1.71 Sec23 homolog A (S. cerevisiae)
DSCR5 1.70 Down syndrome critical region gene 5
SEC22L1 1.70 SEC22 vesicle trafficking protein-like 1 (S. cerevisiae)
PPP1R15A 1.70 Protein phosphatase 1, regulatory (inhibitor) subunit 15A
CCNH 1.70 Cyclin H
Table W2-A. (continued )
Gene Symbol Fold change Gene Title
RNF125 1.70 Ring finger protein 125
KIAA0974 1.70 KIAA0974
ASAH1 1.69 N-acylsphingosine amidohydrolase (acid ceramidase) 1
MGC14376 1.69 Hypothetical protein MGC14376
RBKS 1.69 Ribokinase
PPP2R5C 1.69 Protein phosphatase 2, regulatory subunit B (B56), gamma isoform
TAOK3 1.69 TAO kinase 3
PAPSS2 1.69 3’-phosphoadenosine 5’-phosphosulfate synthase 2
SLC33A1 1.69 Solute carrier family 33 (acetyl-CoA transporter), member 1
ACP6 1.68 Acid phosphatase 6, lysophosphatidic
KIAA1040 1.68 KIAA1040 protein
TRPC1 1.68 Transient receptor potential cation channel, subfamily C, member 1
ANAPC10 1.68 Anaphase promoting complex subunit 10
KIFAP3 1.68 Kinesin-associated protein 3
TRAM1 1.67 Translocation associated membrane protein 1
ME1 1.67 Malic enzyme 1, NADP(+)-dependent, cytosolic
GOT1 1.67 Glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1)
ZNF140 1.67 Zinc finger protein 140 (clone pHZ-39)
SYBL1 1.67 Synaptobrevin-like 1
PHF10 1.67 PHD finger protein 10
MUT 1.67 Methylmalonyl Coenzyme A mutase
SUI1 1.67 Putative translation initiation factor
MTO1 1.67 Mitochondrial translation optimization 1 homolog (S. cerevisiae)
CIRBP 1.67 Cold inducible RNA binding protein
IDH1 1.67 Isocitrate dehydrogenase 1 (NADP+), soluble
BTG1 1.67 B-cell translocation gene 1, anti-proliferative
PPP3R1 1.66 Protein phosphatase 3 (formerly 2B), regulatory subunit B, 19kDa, alpha isoform
(calcineurin B, type I)
XBP1 1.66 X-box binding protein 1
EIF5 1.66 Eukaryotic translation initiation factor 5
WDR19 1.66 WD repeat domain 19
C6orf133 1.66 Chromosome 6 open reading frame 133
ARFGAP3 1.66 ADP-ribosylation factor GTPase activating protein 3
C18orf9 1.66 Chromosome 18 open reading frame 9
KIAA0962 1.66 KIAA0962 protein
CDC27 1.66 Cell division cycle 27
CGI-116 1.65 CGI-116 protein
AIP1 1.65 Atrophin-1 interacting protein 1
LKAP 1.65 Limkain b1
RCHY1 1.65 Ring finger and CHY zinc finger domain containing 1
KIAA1164 1.65 Hypothetical protein KIAA1164
SARS 1.64 Seryl-tRNA synthetase
CDK11 1.64 Cyclin-dependent kinase (CDC2-like) 11
PPM1B 1.64 Protein phosphatase 1B (formerly 2C), magnesium-dependent, beta isoform
TRPC1 1.64 Transient receptor potential cation channel, subfamily C, member 1
CDA08 1.64 T-cell immunomodulatory protein
CRYZL1 1.64 Crystallin, zeta (quinone reductase)-like 1
GTPBP2 1.64 GTP binding protein 2
GABARAPL1 1.64 GABA(A) receptor-associated protein like 1
SAT 1.64 Spermidine/spermine N1-acetyltransferase
PDE4D 1.64 Phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila)
YPEL5 1.64 Yippee-like 5 (Drosophila)
PRKAB2 1.64 Protein kinase, AMP-activated, beta 2 non-catalytic subunit
ODAG 1.64 Ocular development-associated gene
GCL 1.63 Germ cell-less homolog 1 (Drosophila)
GPP34R 1.63 GPP34-related protein
PTEN 1.63 Phosphatase and tensin homolog (mutated in multiple advanced cancers 1)
KIAA1164 1.63 Hypothetical protein KIAA1164
BCAT1 1.63 Branched chain aminotransferase 1, cytosolic
CGI-141 1.63 CGI-141 protein
CBLB 1.63 Cas-Br-M (murine) ecotropic retroviral transforming sequence b
MEF2A 1.63 MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 2A)
MRS2L 1.62 MRS2-like, magnesium homeostasis factor (S. cerevisiae)
MDS006 1.62  006 protein
PDHX 1.62 Pyruvate dehydrogenase complex, component X
GPR2 1.62 G protein-coupled receptor 2
SUPT3H 1.62 Suppressor of Ty 3 homolog (S. cerevisiae)
SECISBP2 1.62 SECIS binding protein 2
SIAH1 1.62 Seven in absentia homolog 1 (Drosophila)
GCLM 1.61 Glutamate-cysteine ligase, modifier subunit
GARS 1.61 Glycyl-tRNA synthetase
PHYH 1.61 Phytanoyl-CoA hydroxylase (Refsum disease)
TLR3 1.61 Toll-like receptor 3
AGA 1.61 Aspartylglucosaminidase
Table W2-A. (continued )
Gene Symbol Fold change Gene Title
APBB2 1.61 Amyloid beta (A4) precursor protein-binding, family B, member 2 (Fe65-like)
UPF3A 1.61 UPF3 regulator of nonsense transcripts homolog A (yeast)
SCARB2 1.61 Scavenger receptor class B, member 2
GOLGA2 1.61 Golgi autoantigen, golgin subfamily a, 2
RAB33B 1.60 RAB33B, member RAS oncogene family
EBAG9 1.60 Estrogen receptor binding site associated, antigen, 9
MGC21416 1.60 Hypothetical protein MGC21416
ZNF36 1.60 Zinc finger protein 36 (KOX 18)
EIF5 1.60 Eukaryotic translation initiation factor 5
SCARB2 1.60 Scavenger receptor class B, member 2
ZFR 1.60 Zinc finger RNA binding protein
CCNB1 1.60 Cyclin B1
WDR41 1.60 WD repeat domain 41
LOC376745 1.60 AG1
PMS2L2 /// PMS2L5 1.60 Postmeiotic segregation increased 2-like 2 /// postmeiotic segregation increased 2-like 5
PRNP 1.60 Prion protein (p27-30) (Creutzfeld-Jakob disease, Gerstmann-Strausler-Scheinker
syndrome)
PLA2G4C 1.60 Phospholipase A2, group IVC (cytosolic, calcium-independent)
RHOBTB1 1.59 Rho-related BTB domain containing 1
VDP 1.59 Vesicle docking protein, p115
GLS 1.59 Glutaminase
ZNF258 1.59 Zinc finger protein 258
PTEN 1.59 Phosphatase and tensin homolog (mutated in multiple advanced cancers 1)
CTBS 1.59 Chitobiase, di-N-acetyl-
MGEA5 1.59 Meningioma expressed antigen 5 (hyaluronidase)
ARHGEF2 1.59 Rho/rac guanine nucleotide exchange factor (GEF) 2
FBXL4 1.59 F-box and leucine-rich repeat protein 4
WDR45 1.58 WD repeat domain 45
SLC35A3 1.58 solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), member A3
SERPINB1 1.58 Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1
ZCCHC8 1.58 Zinc finger, CCHC domain containing 8
NFE2L1 1.58 Nuclear factor (erythroid-derived 2)-like 1
FLJ20344 1.58 Hypothetical protein FLJ20344
STX16 1.58 Syntaxin 16
RIOK3 1.58 RIO kinase 3 (yeast)
CDC16 1.58 CDC16 cell division cycle 16 homolog (S. cerevisiae)
ETFDH 1.58 Electron-transferring-flavoprotein dehydrogenase
POT1 1.58 POT1 protection of telomeres 1 homolog (S. pombe)
GTF2H2 1.57 General transcription factor IIH, polypeptide 2, 44kDa
CDC16 1.57 CDC16 cell division cycle 16 homolog (S. cerevisiae)
ANKRD11 1.57 Ankyrin repeat domain 11
SQSTM1 1.57 Sequestosome 1
SLC1A4 1.57 Solute carrier family 1 (glutamate/neutral amino acid transporter), member 4
MKNK2 1.57 MAP kinase interacting serine/threonine kinase 2
TDE1 1.57 Tumor differentially expressed 1
YIF1 1.57 Yip1 interacting factor homolog (S. cerevisiae)
MGC10765 1.57 Hypothetical protein MGC10765
DBT 1.57 Dihydrolipoamide branched chain transacylase (maple syrup urine disease)
SARA1 1.57 SAR1a gene homolog 1 (S. cerevisiae)
MTO1 1.57 Mitochondrial translation optimization 1 homolog (S. cerevisiae)
MAK10 1.57 MAK10 homolog, amino-acid N-acetyltransferase subunit, (S. cerevisiae)
MOCOS 1.57 Molybdenum cofactor sulfurase
ITCH 1.57 Itchy homolog E3 ubiquitin protein ligase (mouse)
LOC90806 1.57 Similar to RIKEN cDNA 2610307I21
NDEL1 1.57 NudE nuclear distribution gene E homolog like 1 (A. nidulans)
TGDS 1.57 TDP-glucose 4,6-dehydratase
UBPH 1.57 Similar to ubiquitin binding protein
MOAP1 1.57 Modulator of apoptosis 1
ATF6 1.56 Activating transcription factor 6
FAM8A1 1.56 Family with sequence similarity 8, member A1
C14orf143 1.56 Chromosome 14 open reading frame 143
SNX13 1.56 Sorting nexin 13
TDE1 1.56 Tumor differentially expressed 1
NUDT6 1.56 Nudix (nucleoside diphosphate linked moiety X)-type motif 6
WIPI49 1.56 WD40 repeat protein Interacting with phosphoInositides of 49kDa
SLC33A1 1.56 Solute carrier family 33 (acetyl-CoA transporter), member 1
CARS 1.56 Cysteinyl-tRNA synthetase
DFNA5 1.56 Deafness, autosomal dominant 5
ACTR10 1.56 Actin-related protein 10 homolog (S. cerevisiae)
ARL1 1.55 ADP-ribosylation factor-like 1
STC2 1.55 Stanniocalcin 2
SEC23B 1.55 Sec23 homolog B (S. cerevisiae)
USP14 1.55 Ubiquitin specific protease 14 (tRNA-guanine transglycosylase)
FLJ13639 1.55 Hypothetical protein FLJ13639
Table W2-A. (continued )
Gene Symbol Fold change Gene Title
RALA 1.55 V-ral simian leukemia viral oncogene homolog A (ras related)
FLJ10134 1.55 Hypothetical protein FLJ10134
PRSS15 1.55 Protease, serine, 15
CIRBP 1.55 Cold inducible RNA binding protein
BIRC4 1.55 Baculoviral IAP repeat-containing 4
SNAP23 1.55 Synaptosomal-associated protein, 23kDa
GRINL1A 1.55 Glutamate receptor, ionotropic, N-methyl D-aspartate-like 1A
LAMP2 1.55 Lysosomal-associated membrane protein 2
BRP44L 1.55 Brain protein 44-like
IQCB1 1.55 IQ motif containing B1
DJ971N18.2 1.54 Hypothetical protein DJ971N18.2
FLJ20457 1.54 Hypothetical protein FLJ20457
MBNL2 1.54 Muscleblind-like 2 (Drosophila)
COPA 1.54 Coatomer protein complex, subunit alpha
OR7E31P 1.54 PREDICTED: Homo sapiens olfactory receptor, family 7, subfamily E,
member 31 pseudogene
HHLA3 1.54 HERV-H LTR-associating 3
C9orf97 1.53 Chromosome 9 open reading frame 97
CPT1A 1.53 Carnitine palmitoyltransferase 1A (liver)
SMAD1 1.53 SMAD, mothers against DPP homolog 1 (Drosophila)
DDHD2 1.53 DDHD domain containing 2
ATM 1.53 Ataxia telangiectasia mutated (includes complementation groups A, C and D)
FKBP14 1.53 FK506 binding protein 14, 22 kDa
GHITM 1.53 Growth hormone inducible transmembrane protein
THAP10 1.53 THAP domain containing 10
JMJD3 1.53 Jumonji domain containing 3
FLJ23233 1.53 Hypothetical protein FLJ23233
GOLGA1 1.53 Golgi autoantigen, golgin subfamily a, 1
ZMYND11 1.53 Zinc finger, MYND domain containing 11
KIAA0974 1.53 KIAA0974
CYP20A1 1.53 Cytochrome P450, family 20, subfamily A, polypeptide 1
UGCG 1.53 UDP-glucose ceramide glucosyltransferase
PSPH 1.53 Phosphoserine phosphatase
LANCL1 1.52 LanC lantibiotic synthetase component C-like 1 (bacterial)
PTPRG 1.52 Protein tyrosine phosphatase, receptor type, G
PNAS-4 1.52 CGI-146 protein
SUCLG2 1.52 Succinate-CoA ligase, GDP-forming, beta subunit
UBE4A 1.52 Ubiquitination factor E4A (UFD2 homolog, yeast)
SEPHS2 1.52 Selenophosphate synthetase 2
SPATA6 1.52 Spermatogenesis associated 6
SAT 1.52 Spermidine/spermine N1-acetyltransferase
MGC2747 1.52 Hypothetical protein MGC2747
SLC3A2 1.52 Solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2
ATF5 1.52 Activating transcription factor 5
GTF3C3 1.52 General transcription factor IIIC, polypeptide 3, 102kDa
MTHFD2 1.51 Methylene tetrahydrofolate dehydrogenase (NAD+ dependent)
LETMD1 1.51 LETM1 domain containing 1
RWDD2 1.51 RWD domain containing 2
EIF2C3 1.51 Eukaryotic translation initiation factor 2C, 3
CREM 1.51 CAMP responsive element modulator
COPB2 1.51 Coatomer protein complex, subunit beta 2 (beta prime)
ZNF189 1.51 Zinc finger protein 189
MAP2K1IP1 1.51 Mitogen-activated protein kinase kinase 1 interacting protein 1
PRPSAP2 1.51 Phosphoribosyl pyrophosphate synthetase-associated protein 2
KLHL12 1.51 Kelch-like 12 (Drosophila)
C14orf101 1.51 Chromosome 14 open reading frame 101
RAB6C /// RAB6A 1.51 RAB6C, member RAS oncogene family
CALCB 1.51 Calcitonin-related polypeptide, beta
ASAH1 1.51 N-acylsphingosine amidohydrolase (acid ceramidase) 1
FUCA1 1.51 Fucosidase, alpha-L-1, tissue
RRN3 1.51 RRN3 RNA polymerase I transcription factor homolog (yeast)
TRIP4 1.51 Thyroid hormone receptor interactor 4
WRB 1.51 Tryptophan rich basic protein
SERPINI1 1.51 Serine (or cysteine) proteinase inhibitor, clade I (neuroserpin), member 1
KIAA0992 1.51 Palladin
NNT 1.50 Nicotinamide nucleotide transhydrogenase
PMS2L5 1.50 Postmeiotic segregation increased 2-like 5
VAMP4 1.50 Vesicle-associated membrane protein 4
TBL1X 1.50 Transducin (beta)-like 1X-linked
MARS 1.50 Methionine-tRNA synthetase
TTLL1 1.50 Tubulin tyrosine ligase-like family, member 1
CGRRF1 1.50 Cell growth regulator with ring finger domain 1
GOSR2 1.50 Golgi SNAP receptor complex member 2
ARL1 1.50 ADP-ribosylation factor-like 1
TableE W2-B. SAM Analysis of Differentially Expressed Genes: Downregulated Genes.
Gene Symbol Fold change Gene Title
TUBB4 -2.58 Tubulin, beta, 4
INSIG1 -2.53 Insulin induced gene 1
TUBB2 -2.51 Tubulin, beta, 2
TUBB2 -2.45 Tubulin, beta, 2
ADM -2.36 Adrenomedullin
INSIG1 -2.36 Insulin induced gene 1
RGC32 -2.33 Response gene to complement 32
TUBB4 -2.20 Tubulin, beta, 4
PHLDA2 -2.15 Pleckstrin homology-like domain, family A, member 2
EFHD2 -2.07 EF hand domain containing 2
RAC3 -2.04 Ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3)
H2AFX -2.03 H2A histone family, member X
DBP -2.01 D site of albumin promoter (albumin D-box) binding protein
TBX2 -2.00 T-box 2
LMNB2 -2.00 Lamin B2
ASF1B -1.99 ASF1 anti-silencing function 1 homolog B (S. cerevisiae)
PA2G4 -1.97 Proliferation-associated 2G4, 38kDa
UBE2L3 -1.95 Ubiquitin-conjugating enzyme E2L 3
EMP1 -1.95 Epithelial membrane protein 1
GPRC5B -1.94 G protein-coupled receptor, family C, group 5, member B
MRPS12 -1.94 Mitochondrial ribosomal protein S12
FHOD1 -1.93 Formin homology 2 domain containing 1
IFIT1 -1.92 Interferon-induced protein with tetratricopeptide repeats 1
SPHK1 -1.92 Sphingosine kinase 1
NOTCH3 -1.91 Notch homolog 3 (Drosophila)
CDC25A -1.90 Cell division cycle 25A
TWIST1 -1.87 Twist homolog 1 (acrocephalosyndactyly 3; Saethre-Chotzen syndrome) (Drosophila)
ACAT2 -1.87 Acetyl-Coenzyme A acetyltransferase 2 (acetoacetyl Coenzyme A thiolase)
MLP -1.86 MARCKS-like protein
MICB -1.85 MHC class I polypeptide-related sequence B
FKBP4 -1.85 FK506 binding protein 4, 59kDa
NR4A2 -1.84 nuclear receptor subfamily 4, group A, member 2
NR4A2 -1.84 Nuclear receptor subfamily 4, group A, member 2
NRGN -1.84 Neurogranin (protein kinase C substrate, RC3)
HSPB1 -1.83 Heat shock 27kDa protein 1
FDPS -1.83 Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase,
dimethylallyltranstransferase, geranyltranstransferase)
FSCN1 -1.82 Fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus)
IGFBP4 -1.81 Insulin-like growth factor binding protein 4
FLJ23311 -1.81 FLJ23311 protein
TCF3 -1.81 Transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47)
LDLR -1.80 Low density lipoprotein receptor (familial hypercholesterolemia)
GP1BB -1.80 Glycoprotein Ib (platelet), beta polypeptide
SERPINB9 -1.79 Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9
EXOSC4 -1.79 Exosome component 4
NARF -1.78 Nuclear prelamin A recognition factor
EXOSC4 -1.78 Exosome component 4
CA2 -1.77 Carbonic anhydrase II
FLJ10520 -1.77 Hypothetical protein FLJ10520
GEMIN4 -1.76 Gem (nuclear organelle) associated protein 4
TUBB /// MGC8685 -1.76 Tubulin, beta polypeptide
EXOSC4 -1.76 Exosome component 4
TMSNB -1.76 Thymosin, beta, identified in neuroblastoma cells
UBAP2L -1.76 Ubiquitin associated protein 2-like
SLC16A3 -1.76 Solute carrier family 16 (monocarboxylic acid transporters), member 3
UBE2L3 -1.74 Ubiquitin-conjugating enzyme E2L 3
TSAP6 -1.74 Dudulin 2
CCND3 -1.74 Cyclin D3
LIPG -1.74 Lipase, endothelial
EMP2 -1.74 Epithelial membrane protein 2
MRPS12 -1.73 Mitochondrial ribosomal protein S12
FEN1 -1.72 Flap structure-specific endonuclease 1
SCRIB -1.72 Scribbled homolog (Drosophila)
MAC30 -1.71 Hypothetical protein MAC30
DUSP6 -1.71 Dual specificity phosphatase 6
MCM4 -1.70 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae)
ALDOC -1.70 Aldolase C, fructose-bisphosphate
BID -1.70 BH3 interacting domain death agonist
CCNF -1.70 Cyclin F
MSF -1.70 MLL septin-like fusion
CTGF -1.70 Connective tissue growth factor
M6PRBP1 -1.69 Mannose-6-phosphate receptor binding protein 1
HIP1 -1.69 Huntingtin interacting protein 1
Table W2-B. (continued )
Gene Symbol Fold change Gene Title
CYP26B1 -1.69 Cytochrome P450, family 26, subfamily B, polypeptide 1
BASP1 -1.69 Brain abundant, membrane attached signal protein 1
BIRC5 -1.69 Baculoviral IAP repeat-containing 5 (survivin)
DNAJB1 -1.69 DnaJ (Hsp40) homolog, subfamily B, member 1
HSPC111 -1.68 Hypothetical protein HSPC111
MCM7 -1.68 MCM7 minichromosome maintenance deficient 7 (S. cerevisiae)
STRA13 -1.68 Stimulated by retinoic acid 13
PPIF -1.68 Peptidylprolyl isomerase F (cyclophilin F)
SCD -1.68 Stearoyl-CoA desaturase (delta-9-desaturase)
TK1 -1.68 Thymidine kinase 1, soluble
DHCR7 -1.68 7-dehydrocholesterol reductase
GRSF1 -1.67 G-rich RNA sequence binding factor 1
GPC1 -1.67 Glypican 1
INSIG1 -1.67 Insulin induced gene 1
NR4A2 -1.67 Nuclear receptor subfamily 4, group A, member 2
SLC25A1 -1.67 Solute carrier family 25 (mitochondrial carrier; citrate transporter), member 1
C19orf28 -1.67 Chromosome 19 open reading frame 28
EBP -1.67 Emopamil binding protein (sterol isomerase)
LDLR -1.66 Low density lipoprotein receptor (familial hypercholesterolemia)
BID -1.66 BH3 interacting domain death agonist
PKM2 -1.66 Pyruvate kinase, muscle
SDC1 -1.66 Syndecan 1
CENPB -1.65 Centromere protein B, 80kDa
TKT -1.65 Transketolase (Wernicke-Korsakoff syndrome)
KIAA0186 -1.65 KIAA0186 gene product
GGA2 -1.65 Golgi associated, gamma adaptin ear containing, ARF binding protein 2
GADD45B -1.65 Growth arrest and DNA-damage-inducible, beta
MGC4083 -1.65 Tubulin beta MGC4083
MAC30 -1.65 Hypothetical protein MAC30
DDX39 -1.65 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39
CHC1 -1.65 Chromosome condensation 1
DNAJB1 -1.64 DnaJ (Hsp40) homolog, subfamily B, member 1
GEMIN4 -1.64 Gem (nuclear organelle) associated protein 4
CALML4 -1.64 Calmodulin-like 4
NUP62 -1.64 Nucleoporin 62kDa
UBE2C -1.64 Ubiquitin-conjugating enzyme E2C
ABCA1 -1.64 ATP-binding cassette, sub-family A (ABC1), member 1
CYR61 -1.64 Cysteine-rich, angiogenic inducer, 61
RPS6KA1 -1.64 Ribosomal protein S6 kinase, 90kDa, polypeptide 1
SHD1 -1.64 Likely ortholog of mouse Sac3 homology domain 1 (S. cerevisiae)
TBX2 -1.64 T-box 2
NASP -1.64 Nuclear autoantigenic sperm protein (histone-binding)
SNF1LK -1.63 SNF1-like kinase
TPST2 -1.63 Tyrosylprotein sulfotransferase 2
SLCO4A1 -1.63 Solute carrier organic anion transporter family, member 4A1
SCARB1 -1.62 Scavenger receptor class B, member 1
PSME3 -1.62 Proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki)
SLC7A6 -1.62 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 6
EBP -1.62 Emopamil binding protein (sterol isomerase)
C20orf27 -1.62 Chromosome 20 open reading frame 27
RFC5 -1.62 Replication factor C (activator 1) 5, 36.5kDa
IRF3 -1.62 Interferon regulatory factor 3
Pfs2 -1.62 DNA replication complex GINS protein PSF2
FEN1 -1.62 Flap structure-specific endonuclease 1
GMNN -1.62 Geminin, DNA replication inhibitor
LPHN1 -1.62 Latrophilin 1
CDCA3 -1.61 Cell division cycle associated 3
NEFH -1.61 Neurofilament, heavy polypeptide 200kDa
TREX2 -1.61 Three prime repair exonuclease 2
RRM2 -1.61 Ribonucleotide reductase M2 polypeptide
SIX2 -1.61 Sine oculis homeobox homolog 2 (Drosophila)
C16orf34 -1.61 Chromosome 16 open reading frame 34
DHCR7 -1.61 7-dehydrocholesterol reductase
SAP18 -1.61 Sin3-associated polypeptide, 18kDa
H3F3B -1.61 H3 histone, family 3B (H3.3B)
TUBG1 -1.61 Tubulin, gamma 1
APBA2 -1.61 Amyloid beta (A4) precursor protein-binding, family A, member 2 (X11-like)
RIS1 -1.60 Ras-induced senescence 1
ITPKA -1.60 Inositol 1,4,5-trisphosphate 3-kinase A
PHB -1.60 Prohibitin
PDE4A -1.60 Phosphodiesterase 4A, cAMP-specific (phosphodiesterase E2 dunce homolog,
Drosophila)
BPGM -1.60 2,3-bisphosphoglycerate mutase
Table W2-B. (continued )
Gene Symbol Fold change Gene Title
DIPA -1.60 Hepatitis delta antigen-interacting protein A
H1FX -1.60 H1 histone family, member X
MYL9 -1.59 Myosin, light polypeptide 9, regulatory
DDX23 -1.59 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23
KIAA0657 -1.59 KIAA0657 protein
MCM7 -1.59 MCM7 minichromosome maintenance deficient 7 (S. cerevisiae)
HHEX -1.59 Hematopoietically expressed homeobox
GBX2 -1.59 Gastrulation brain homeo box 2
GTSE1 -1.59 G-2 and S-phase expressed 1
SKP2 -1.59 S-phase kinase-associated protein 2 (p45)
SLC16A3 -1.59 Solute carrier family 16 (monocarboxylic acid transporters), member 3
IFI30 -1.59 Interferon, gamma-inducible protein 30
PSMD11 -1.58 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 11
SOX18 -1.58 SRY (sex determining region Y)-box 18
CCNE1 -1.58 Cyclin E1
K-ALPHA-1 -1.58 Tubulin, alpha, ubiquitous
OK/SW-cl.56 -1.58 Beta 5-tubulin
GNB1L -1.58 Guanine nucleotide binding protein (G protein), beta polypeptide 1-like
DDX23 -1.58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23
MYBL2 -1.58 V-myb myeloblastosis viral oncogene homolog (avian)-like 2
FLJ13912 -1.58 Hypothetical protein FLJ13912
GTSE1 -1.58 G-2 and S-phase expressed 1
AK1 -1.57 Adenylate kinase 1
PCNA -1.57 Proliferating cell nuclear antigen
ACTN1 -1.57 Actinin, alpha 1
LPHN1 -1.56 Latrophilin 1
TREX2 -1.56 Three prime repair exonuclease 2
MCM2 -1.56 MCM2 minichromosome maintenance deficient 2, mitotin (S. cerevisiae)
FASN -1.56 Fatty acid synthase
FGFR4 -1.56 Fibroblast growth factor receptor 4
TACC3 -1.56 Transforming, acidic coiled-coil containing protein 3
GEMIN6 -1.56 Gem (nuclear organelle) associated protein 6
OK/SW-cl.56 -1.56 Beta 5-tubulin
NSDHL -1.56 NAD(P) dependent steroid dehydrogenase-like
SIX2 -1.56 Sine oculis homeobox homolog 2 (Drosophila)
CSRP2 -1.56 Cysteine and glycine-rich protein 2
FDFT1 -1.56 Farnesyl-diphosphate farnesyltransferase 1
BICD2 -1.56 Bicaudal D homolog 2 (Drosophila)
AURKB -1.56 Aurora kinase B
OK/SW-cl.56 -1.55 Beta 5-tubulin
CCND1 -1.55 Cyclin D1 (PRAD1: parathyroid adenomatosis 1)
FLJ13479 -1.55 Hypothetical protein FLJ13479
MAC30 -1.55 Hypothetical protein MAC30
CHAF1A -1.55 Chromatin assembly factor 1, subunit A (p150)
CCNF -1.55 Cyclin F
CKS2 -1.55 CDC28 protein kinase regulatory subunit 2
TYRO3 -1.55 TYRO3 protein tyrosine kinase
FOXM1 -1.55 Forkhead box M1
TCF7L1 -1.55 Transcription factor 7-like 1 (T-cell specific, HMG-box)
FLJ10647 -1.55 Hypothetical protein FLJ10647
SIVA -1.55 CD27-binding (Siva) protein
SLC6A8 -1.54 Solute carrier family 6 (neurotransmitter transporter, creatine), member 8
CDC25A -1.54 Cell division cycle 25A
FLJ10647 -1.54 Hypothetical protein FLJ10647 /// hypothetical protein FLJ10647
RAI -1.54 RelA-associated inhibitor
NRTN -1.54 Neurturin
RGS3 -1.54 Regulator of G-protein signalling 3
HSPC111 -1.54 Hypothetical protein HSPC111
TP53I11 -1.54 Tumor protein p53 inducible protein 11
CORO1A -1.54 Coronin, actin binding protein, 1A
GTSE1 -1.54 G-2 and S-phase expressed 1
CKB -1.54 Creatine kinase, brain
MUF1 -1.53 MUF1 protein
HRAS -1.53 V-Ha-ras Harvey rat sarcoma viral oncogene homolog
CTDSPL -1.53 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small
phosphatase-like
DDA3 -1.53 Differential display and activated by p53
SLC2A6 -1.53 Solute carrier family 2 (facilitated glucose transporter), member 6
UBAP2L -1.53 Ubiquitin associated protein 2-like
BICD2 -1.53 Bicaudal D homolog 2 (Drosophila)
RRM2 -1.53 Ribonucleotide reductase M2 polypeptide
CKIP-1 -1.52 CK2 interacting protein 1; HQ0024c protein
ACLY -1.52 ATP citrate lyase
Table W2-B. (continued )
Gene Symbol Fold change Gene Title
FLJ20186 -1.52 Hypothetical protein FLJ20186
MICA /// MICB -1.52 MHC class I polypeptide-related sequence A /// MHC class I polypeptide-related
sequence B
PAFAH1B3 -1.52 Platelet-activating factor acetylhydrolase, isoform Ib, gamma subunit 29kDa
BICD2 -1.52 Bicaudal D homolog 2 (Drosophila)
LMNA -1.52 Lamin A/C
MAP2K3 -1.52 Mitogen-activated protein kinase kinase 3
PPIF -1.52 Peptidylprolyl isomerase F (cyclophilin F)
GAS2L1 -1.51 Growth arrest-specific 2 like 1
MCM4 -1.51 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae)
ORC1L -1.51 Origin recognition complex, subunit 1-like (yeast)
DHCR24 -1.51 24-dehydrocholesterol reductase
PLXNA1 -1.51 Plexin A1
K-ALPHA-1 -1.51 Tubulin, alpha, ubiquitous
CSRP2 -1.51 Cysteine and glycine-rich protein 2
SMTN -1.51 Smoothelin
PLAUR -1.51 Plasminogen activator, urokinase receptor
TKT -1.51 Transketolase (Wernicke-Korsakoff syndrome)
FLJ23469 -1.51 Hypothetical protein FLJ23469
RFC5 -1.50 Replication factor C (activator 1) 5, 36.5kDa
PTMA -1.50 Prothymosin, alpha (gene sequence 28)
UBADC1 -1.50 Ubiquitin associated domain containing 1
LOC51337 -1.50 Mesenchymal stem cell protein DSCD75
SCGF -1.50 Stem cell growth factor; lymphocyte secreted C-type lectin
ZBTB7 -1.50 Zinc finger and BTB domain containing 7
TCF3 -1.50 Transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47)
